Logo

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

Share this
Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

Akeso Reports First Patient Dosing in P-III Trial of Ivonescimab for the Treatment of Non-Squamous Non-Small Cell Lung Cancer

Shots:

  • The 1st patient has been dosed in a P-III registrational trial to evaluate the efficacy & safety of Ivonescimab (PD-1/VEGF bi-specific Ab) + CT vs PBO + CT in 320 patients with LA or metastatic nsq. NSCLC with EGFR mutation failed after EGFR-TKI treatment
  • The 1EPs of the study is PFS as assessed by IRRC. In the early clinical studies in Australia & China, Ivonescimab showed good safety & tolerability for multiple types of lung cancer, including NSCLC & SCLC with good anti-tumor effects
  • Additionally, Ivonescimab also has the effect of stimulating antitumor immune responses & inhibiting tumor angiogenesis. The company is planning to initiate the P-III trial of Ivonescimab for SCLC

Ref: PR Newswire | Image: South China Morning Post

Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions